Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Atezolizumab in Advanced Solid Tumors (Japan)
jRCT2080222162Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab in Nonhematologic neoplasms (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of atezolizumab. Started Jul 2013; status: completed.
02
Drugs
atezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080222162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222162.